The Broadest Liver In Vitro Model Portfolio in the Marketplace
Carol Tomaszewski2022-01-10T11:11:39-05:00Over the last several years, Visikol has worked to build out its liver cell culture capabilities from solely [...]
Assessing Promising NASH Compounds
Carol Tomaszewski2021-08-31T10:52:03-05:00Nonalcoholic steatohepatitis (NASH) is a disease of the liver characterized by inflammation, cell injury and fibrosis. Progression of this [...]
PHH, HepG2 or HepaRG for Drug Induced Liver Injury Studies?
Griffin Ferrara2020-11-30T14:35:00-05:00Drug-induced liver injury (DILI) is one of the most frequent causes of safety-related drug marketing withdrawal, according to the [...]